Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Scaffolding to build a rational vaccine design strategy.

Literature DB >> 20937874

Scaffolding to build a rational vaccine design strategy.

Dennis R Burton¹.

Abstract

Mesh：

Substances：

Year: 2010 PMID： 20937874 PMCID： PMC2964222 DOI： 10.1073/pnas.1012923107

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

× No keyword cloud information.

20 in total

Review 1. Antibodies, viruses and vaccines.

Authors: Dennis R Burton
Journal: Nat Rev Immunol Date: 2002-09 Impact factor: 53.106

2. Elicitation of structure-specific antibodies by epitope scaffolds.

Authors: Gilad Ofek; F Javier Guenaga; William R Schief; Jeff Skinner; David Baker; Richard Wyatt; Peter D Kwong
Journal: Proc Natl Acad Sci U S A Date: 2010-09-27 Impact factor: 11.205

3. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Authors: Gilad Ofek; Krisha McKee; Yongping Yang; Zhi-Yong Yang; Jeff Skinner; F Javier Guenaga; Richard Wyatt; Michael B Zwick; Gary J Nabel; John R Mascola; Peter D Kwong
Journal: J Virol Date: 2009-12-30 Impact factor: 5.103

4. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Authors: Jean-Philippe Julien; Nerea Huarte; Rubén Maeso; Stefka G Taneva; Annie Cunningham; José L Nieva; Emil F Pai
Journal: J Virol Date: 2010-02-10 Impact factor: 5.103

Review 5. The role of antibodies in HIV vaccines.

Authors: John R Mascola; David C Montefiori
Journal: Annu Rev Immunol Date: 2010 Impact factor: 28.527

6. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

Authors: G Stiegler; R Kunert; M Purtscher; S Wolbank; R Voglauer; F Steindl; H Katinger
Journal: AIDS Res Hum Retroviruses Date: 2001-12-10 Impact factor: 2.205

7. Confocal microscopy of giant vesicles supports the absence of HIV-1 neutralizing 2F5 antibody reactivity to plasma membrane phospholipids.

Authors: Beatriz Apellaniz; Ana J García-Sáez; Nerea Huarte; Renate Kunert; Karola Vorauer-Uhl; Hermann Katinger; Petra Schwille; José L Nieva
Journal: FEBS Lett Date: 2010-03-17 Impact factor: 4.124

8. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.

Authors: Bruno E Correia; Yih-En Andrew Ban; Margaret A Holmes; Hengyu Xu; Katharine Ellingson; Zane Kraft; Chris Carrico; Erica Boni; D Noah Sather; Camille Zenobia; Katherine Y Burke; Tyler Bradley-Hewitt; Jessica F Bruhn-Johannsen; Oleksandr Kalyuzhniy; David Baker; Roland K Strong; Leonidas Stamatatos; William R Schief
Journal: Structure Date: 2010-09-08 Impact factor: 5.006

9. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors: M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal: J Virol Date: 2001-11 Impact factor: 5.103

10. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors: Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal: J Virol Date: 2009-11-11 Impact factor: 5.103

31 in total

Scaffolding to build a rational vaccine design strategy.

Review 1. Antibodies, viruses and vaccines.

2. Elicitation of structure-specific antibodies by epitope scaffolds.

3. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

4. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Review 5. The role of antibodies in HIV vaccines.

6. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

7. Confocal microscopy of giant vesicles supports the absence of HIV-1 neutralizing 2F5 antibody reactivity to plasma membrane phospholipids.

8. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.

9. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

10. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Review 1. Immunological memory ≠ protective immunity.

Review 2. Computational tools for epitope vaccine design and evaluation.

Review 3. What does it mean to develop an HIV vaccine by rational design?

Review 4. Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.

5. Vaccines, reverse vaccinology, and bacterial pathogenesis.

6. Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer.

7. Type VI secretion system sheaths as nanoparticles for antigen display.

Review 8. Protein engineering strategies for the development of viral vaccines and immunotherapeutics.

Review 9. Vaccine design: emerging concepts and renewed optimism.

10. Trimerization of the HIV Transmembrane Domain in Lipid Bilayers Modulates Broadly Neutralizing Antibody Binding.